Insmed Incorporated
INSM
Updated: 22/09/2026, 20:13:10
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
No summaries found.
- Share price
- $120.53
- Market cap
- $26.13B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- William H. Lewis
- Employees
- 1,664
- IPO date
- 01/06/2000
- Beta
- 0.8169999999999999
- Last dividend
- $0.00
- Day range
- $119.26 – $121.66
- 52-week range
- $90.39 – $212.75
- 1-day performance
- -0.39%
- 1-year performance
- 33.35%
- Current drawdown (1Y)
- -43.35%
- CIK
- 0001104506
- CUSIP
- 457669307
- ISIN
- US4576693075
- Created
- 07/12/2025, 04:44:20
- Last update
- 22/09/2026, 20:13:10
Track Insmed Incorporated with an AI analyst
See which prediction-market events move INSM, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 09/06/2026, 15:22:09
Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 20/05/2026, 14:50:56
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus
MarketBeat • STOCK • 18/05/2026, 05:04:09
Insmed (NASDAQ: INSM) Stock Analysis: Price Target Update and Q1 2026 Earnings Review
Market Data • Market Data • 13/05/2026, 21:14:24
Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/05/2026, 21:20:46
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
Zacks Investment Research • STOCK • 08/05/2026, 13:06:26
Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 07/05/2026, 16:51:18
Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
PRNewsWire • STOCK • 06/05/2026, 18:30:00
Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
PRNewsWire • STOCK • 04/05/2026, 09:00:00
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure
Zacks Investment Research • STOCK • 08/04/2026, 11:41:11
Insmed discontinues development of skin condition drug after mid-stage study miss
Reuters • STOCK • 07/04/2026, 18:32:17
Insmed Provides Clinical Update on Phase 2b CEDAR Study
PRNewsWire • STOCK • 07/04/2026, 18:01:00